Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2770

Sort by

Sort Order Select

Journal Articles

Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China

De Zhou, Xianbo Huang, Lixia Zhu, Xuelian Hu, Xiudi Yang, Mixue Xie, Xin Huang, Fang Yu, Juying Wei, Liya Ma, Jingjing Zhu, Shuqi Zhao, Wanzhuo Xie, Hongyan Tong, Jie Jin, Xiujin Ye

Blood (2025) 146 (3): 318–327.

https://doi.org/10.1182/blood.2024026139

Published: 2025

Includes: Supplemental data

Journal Articles

HNRNPC and m 6 A RNA methylation control oncogenic transcription and metabolism in T-cell leukemia

Blood (2025) 146 (3): 275–290.

https://doi.org/10.1182/blood.2024026848

Published: 2025

Includes: Supplemental data

Journal Articles

Secondary blastoid plasma cell leukemia: can an old dog learn new tricks?

Jinjun Cheng, Jiehao Zhou

Blood (2025) 146 (3): 396.

https://doi.org/10.1182/blood.2025029282

Published: 2025

Journal Articles

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

Blood (2025) 146 (3): 291–303.

https://doi.org/10.1182/blood.2024028064

Published: 2025

Includes: Supplemental data

Journal Articles

Visualizing amyloidosis: The role of radionuclide imaging in systemic amyloidosis

Nirija Ranjit Anderson, Sharmila Dorbala, Peter Mollee

Blood blood.2024026386.

https://doi.org/10.1182/blood.2024026386

Published: 2025

Journal Articles

The Treatment of Marginal Zone Lymphoma

Juan Pablo Alderuccio, Ariela Noy

Blood blood.2024028269.

https://doi.org/10.1182/blood.2024028269

Published: 2025

Journal Articles

A New Prognostic Index (CLIPI) for Advanced Cutaneous Lymphoma Enables Precise Patient Risk Stratification

Julia J Scarisbrick, Pietro Quaglino, Sean J Whittaker, Martine Bagot, Emmanuella Guenova, Evangelia Papadavid, H. Miles Prince, Jose Antonio Sanches, Denis Miyashiro, Octavio Servitje, Christiane Querfeld, Oleg E Akilov, Arvind Arumainathan, Luke Bennett, Maxime Battistella, Kim Benstead, Dr, Emilio francesco Berti, Marie Beylot-Barry, Anne-Marie Busschots, Richard Andrew Cowan, Reinhard Dummer, Giles Dunnill, Maria Teresa Estrach, Felicity Evison, Abraham Ellahi Bashir, Larisa J Geskin, Alejandro Gru, Joan Guitart, Melba C Herrera, Emmilia Hodak, Steven M Horwitz, Constanze Jonak, Claus-Detlev Klemke, Robert Knobler, Pamela McKay, Marta Marschalkó, Cesare Massone, Rubeta Matin, Christina Mitteldorf, Roberto Andres Novoa, Pablo L. Ortiz-Romero, Nicola Pimpinelli, Ramon M Pujol, Annmari Ranki, Liisa Vankeva, Kerri E. Rieger, Rudolf Stadler, Franz Trautinger, Johanna Latzka, Maarten H. Vermeer, Rachel Wachsmuth, Sophie Weatherhead, Ulrike Wehkamp, Marion Wobser, Youn H Kim

Blood blood.2025029628.

https://doi.org/10.1182/blood.2025029628

Published: 2025

Journal Articles

Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomics

Raymond K.H. Yip, Jeremy Er, Lei Qin, Quoc Hoang Nguyen, Allan Motyer, Joel S Rimes, Amanda Light, Ruvimbo D Mishi, Ling Ling, Casey J.A. Anttila, Ellen Tsui, Daniela Amann-Zalcenstein, Mark R Dowling, Kelly L. Rogers, Rory Bowden, Yunshun Chen, Simon J Harrison, Edwin D Hawkins

Blood blood.2025028896.

https://doi.org/10.1182/blood.2025028896

Published: 2025

Includes: Multimedia, Supplemental data

Journal Articles

Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma

Blood (2025) 146 (2): 178–190.

https://doi.org/10.1182/blood.2024026622

Published: 2025

Includes: Supplemental data

Journal Articles

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma

Blood (2025) 146 (2): 167–177.

https://doi.org/10.1182/blood.2024026216

Published: 2025

Includes: Supplemental data

Journal Articles

Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia

Brian T. Grainger, Philip A. Thompson, Chan Y. Cheah

Blood (2025) 146 (2): 145–154.

https://doi.org/10.1182/blood.2024024893

Published: 2025

Journal Articles

A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL

Min Guo, Tugba Memis, Alena Sophie Ehrmann, Anselm Pittrof, Bernd Baumann, Francesca Ferrante, Eugen Tausch, Kirsten Fischer, Hartmut Döhner, Tilman Borggrefe, Stephan Stilgenbauer, Ulrich Pannicke, Klaus Schwarz, Daniel Mertens, Franz Oswald

Blood blood.2025028529.

https://doi.org/10.1182/blood.2025028529

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world data provide a CARbon copy for ide-cel

Timothy Schmidt

Blood (2025) 146 (2): 131–133.

https://doi.org/10.1182/blood.2025029274

Published: 2025

Journal Articles

Silence of the myeloma clones: GPRC5D epigenetic regulation

Holly Lee, Nizar J. Bahlis

Blood (2025) 146 (2): 133–135.

https://doi.org/10.1182/blood.2025028865

Published: 2025

Journal Articles

Beware the zombie enzyme

David Dominguez-Sola

Blood (2025) 146 (2): 135–136.

https://doi.org/10.1182/blood.2025028953

Published: 2025

Journal Articles

Reshaping the TME to enhance checkpoint blockade in ENKTL

Annika Dechow, Till Braun

Blood (2025) 146 (2): 129–131.

https://doi.org/10.1182/blood.2025028917

Published: 2025

Journal Articles

A rare phenotype of peripheral T-cell lymphoma, NOS: coexpression of CD15, CD20, and T follicular helper markers in a DUSP22 alt case

Muna Al Jabri, Ali Sakhdari

Blood (2025) 146 (2): 260.

https://doi.org/10.1182/blood.2025028986

Published: 2025

Journal Articles

Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma

Blood (2025) 146 (2): 155–166.

https://doi.org/10.1182/blood.2024027109

Published: 2025

Includes: Supplemental data

Journal Articles

Blunted CD40-responsive enhancer activation in CREBBP -mutant lymphomas can be restored by enforced CD4 T-cell engagement

Blood (2025) 146 (2): 191–205.

https://doi.org/10.1182/blood.2024026664

Published: 2025

Includes: Supplemental data

Journal Articles

Immune Alterations in Myeloma Evolution and Outcomes: Quo Vadis?

Madhav V. Dhodapkar, Bruno Paiva

Blood blood.2024026227.

https://doi.org/10.1182/blood.2024026227

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China

HNRNPC and m 6 A RNA methylation control oncogenic transcription and metabolism in T-cell leukemia

Secondary blastoid plasma cell leukemia: can an old dog learn new tricks?

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

Visualizing amyloidosis: The role of radionuclide imaging in systemic amyloidosis

The Treatment of Marginal Zone Lymphoma

A New Prognostic Index (CLIPI) for Advanced Cutaneous Lymphoma Enables Precise Patient Risk Stratification

Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomics

Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma

Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia

A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL

Real-world data provide a CARbon copy for ide-cel

Silence of the myeloma clones: GPRC5D epigenetic regulation

Beware the zombie enzyme

Reshaping the TME to enhance checkpoint blockade in ENKTL

A rare phenotype of peripheral T-cell lymphoma, NOS: coexpression of CD15, CD20, and T follicular helper markers in a DUSP22 alt case

Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma

Blunted CD40-responsive enhancer activation in CREBBP -mutant lymphomas can be restored by enforced CD4 T-cell engagement

Immune Alterations in Myeloma Evolution and Outcomes: Quo Vadis?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only